Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Fuso Pharmaceutical Industries's Enterprise Value for the quarter that ended in Mar. 2026 was 円43,789 Mil.
Fuso Pharmaceutical Industries's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円3,064 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fuso Pharmaceutical Industries EV-to-EBIT Related Terms
Fuso Pharmaceutical Industries EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Fuso Pharmaceutical Industries's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fuso Pharmaceutical Industries EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Fuso Pharmaceutical Industries's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Fuso Pharmaceutical Industries's EV-to-EBIT falls into.
Fuso Pharmaceutical Industries's current Enterprise Value is 円41,353 Mil.
Fuso Pharmaceutical Industries's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円3,064 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fuso Pharmaceutical Industries (TSE:4538) has a EV-to-EBIT of 13.50 as of Aug. 30, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Fuso Pharmaceutical Industries and its competitors. This is 10% below median its historical median of 15.04. Over the past decade, Fuso Pharmaceutical Industries' EV-to-EBIT has ranged from 9.17 to 95.75. According to the industry distribution chart, Fuso Pharmaceutical Industries ranks #295 out of 685 companies in the Drug Manufacturers industry, placing it in the top 43.1%.
Is Fuso Pharmaceutical Industries' EV-to-EBIT too high?
Fuso Pharmaceutical Industries' current EV-to-EBIT of 13.50 is 10% below median its 10-year median of 15.04. Over the past 10 years, this metric has ranged from a low of 9.17 to a high of 95.75. The Drug Manufacturers industry median EV-to-EBIT is 16.22. Fuso Pharmaceutical Industries' value of 13.50 is 16.8% below this industry median. Based on the distribution chart, Fuso Pharmaceutical Industries ranks #295 out of 685 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Fuso Pharmaceutical Industries has a GF Score™ of 57/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Fuso Pharmaceutical Industries' EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Fuso Pharmaceutical Industries ranks #295 out of 685 companies for EV-to-EBIT. This puts Fuso Pharmaceutical Industries in the upper half of its industry. The industry median EV-to-EBIT is 16.22. Fuso Pharmaceutical Industries' value of 13.50 is 16.8% below this benchmark. Historically, Fuso Pharmaceutical Industries' own EV-to-EBIT has ranged from 9.17 to 95.75 over the past decade. While the company's 10-year median is 15.04 vs. the industry median of 16.22, Fuso Pharmaceutical Industries has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 16.22, based on 685 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fuso Pharmaceutical Industries's current EV-to-EBIT of 13.50 is 16.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Fuso Pharmaceutical Industries and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 16.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fuso Pharmaceutical Industries's current EV-to-EBIT is 13.50, which is 10% below median its own 10-year median of 15.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fuso Pharmaceutical Industries stock overvalued right now?
Based on GuruFocus' analysis, Fuso Pharmaceutical Industries (TSE:4538) is currently considered Modestly Undervalued. The stock's GF Value™ is 円2,589.65, compared to a current price of 円2,298.00 — trading 11.3% below its estimated fair value. The current EV-to-EBIT is 13.50, which is 10% below median its 10-year median of 15.04 and 16.8% below the Drug Manufacturers industry median of 16.22. Fuso Pharmaceutical Industries' overall GF Score™ is 57/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Fuso Pharmaceutical Industries (TSE:4538), the current EV-to-EBIT is 13.50 as of Aug. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fuso Pharmaceutical Industries (TSE:4538) Overvalued in 2026?
Based on GuruFocus' analysis, Fuso Pharmaceutical Industries stock appears to be undervalued.
The current stock price of 円2,298.00 is trading 11.3% below its estimated GF Value™ of 円2,589.65.
GuruFocus considers Fuso Pharmaceutical Industries to be Modestly Undervalued.
Key valuation signals for TSE:4538:
EV-to-EBIT: 13.50 (10% below median its 10-year median of 15.04)
GF Value™: 円2,589.65 vs. price of 円2,298.00 (11.3% below fair value)
Industry Position: 16.8% below the Drug Manufacturers median (#295 of 685)
No single metric tells the full story. See the TSE:4538 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fuso Pharmaceutical Industries Ltd. is engaged in the manufacture and sale of pharmaceuticals and medical equipment. The company's main products are transfusion fluid and artificial kidney dialysis fluid. Company also includes real estate segment.
57GF Score
Get the complete analysis for TSE:4538
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4538 has been successfully added to your 
